Development of NLRP3 Inflammasome inhibitors as curative drugs for cardiometabolic diseases

DOI: https://doi.org/10.54985/peeref.2401w8293264

---

Cardiometabolic diseases are a group of diseases which include cardiovascular diseases and metabolic syndromes which all affect cardiovascular health. This group of diseases is the leading cause of mortality worldwide. They are often managed by lifestyle modification, pharmacotherapy and surgery. Our research aims to seek and develop drugs that will provide a cure by targeting the NLRP3 inflammasome, a key player in inflammatory processes associated with these diseases. The NLRP3 inflammasome promotes the events that lead to the progression of these diseases and culminate in cardiac remodelling and ultimately heart failure. By meticulously studying and selecting NLRP3 inhibitors, we believe we can develop innovative treatments that not only alleviate symptoms but also address the root causes of cardiometabolic disorders. The potential impact is enormous, promising a new era in personalized medicine and offering hope for millions worldwide.